<div id="readability-page-1"><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>The United Laboratories International Holdings ( (HK:3933) ) has provided an update. The United Laboratories International Holdings has called its annual general meeting for 23 June 2026 in Hong Kong, where shareholders will review and adopt the audited financial statements and directors’ and auditor’s reports for the year ended 31 December 2025, and consider a proposed final dividend. The meeting will also vote on the re-election of two executive directors and one independent non-executive director, the reappointment of Deloitte Touche Tohmatsu as auditor, and a mandate allowing the board to issue up to 20% of existing share capital, potentially expanded by shares repurchased, providing the company with flexibility for future capital-raising and corporate actions. The most recent analyst rating on (HK:3933) stock is a Buy with a HK$20.00 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page. More about The United Laboratories International Holdings The United Laboratories International Holdings Limited is a pharmaceutical company incorporated in the Cayman Islands and listed in Hong Kong. The group focuses on manufacturing and distributing pharmaceutical products, operating primarily in Hong Kong and mainland China, and is overseen by a board comprising executive and independent non-executive directors. Average Trading Volume: 10,967,076 Technical Sentiment Signal: Hold Current Market Cap: HK$18.82B See more data about 3933 stock on TipRanks’ Stock Analysis page.</div>

03933

520500

159837

United Laboratories International Holdings has scheduled its annual general meeting for June 23, 2026, in Hong Kong. Shareholders will review financial statements, consider a proposed dividend, and vote on the re-election of directors and auditor reappointment. The company seeks a mandate to issue up to 20% of existing share capital for future capital-raising. The stock currently has a Buy rating with a price target of HK$20.00 and a market cap of HK$18.82B.

Tip Ranks

UNITED LAB

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

E Fund CSI Biotechnology Theme ETF

Penghua SSE STAR Biology and Medicine ETF

Guotai CSI Bio-medicine ETF

Huaan Hang Seng Biotech ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Ping An CSI Medicine and Medical Device Innovation ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Penghua CSI HK Connect Health Care Composite ETF

Bosera Hang Seng Health Care ETF(QDII)

Hwabao WP CSI Pharmaceuticals ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Tianhong CNI BIOMEDICINE ETF

China Merchants CSI Biotechnology Theme ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Minsheng Royal CSI Biotechnology Theme ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ICBCCS SSE STAR Biology and Medicine ETF

E Fund CSI 300 Health Care ETF

China Southern Hang Seng Biotech ETF(QDII)

United Laboratories Sets June 2026 AGM, Seeks Fresh Share Issuance Mandate